E. Xia

发表

Selective small-molecule inhibition of an RNA structural element

John J. Cummings, T. Roemer, T. Fischmann, 2015, Nature.

Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein

S. Peltz, X. Tong, Z. Gu, 2013, Antimicrobial Agents and Chemotherapy.

Identification of HCV protease inhibitor resistance mutations by selection pressure-based method

X. Tong, P. Qiu, J. Greene, 2009, Nucleic acids research.

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.

X. Tong, H. Huang, E. Xia, 2009, Antiviral research.

Characterization of monoclonal antibodies that specifically recognize the palm subdomain of hepatitis C virus nonstructural protein 5B polymerase.

Z. Hong, W. Zhong, B. Sodowich, 2001, Virus research.

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.

Rebecca T. Ruck, E. Asante-Appiah, Kung-I Feng, 2017, Journal of medicinal chemistry.

Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2

E. Asante-Appiah, P. Qiu, F. Lahser, 2019, Antimicrobial Agents and Chemotherapy.

MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.

E. Asante-Appiah, M. Dwyer, A. Nomeir, 2018, Bioorganic & medicinal chemistry letters.

Characterization of resistance mutations against HCV ketoamide protease inhibitors.

X. Tong, R. Ralston, Zhuyan Guo, 2008, Antiviral research.

Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease

X. Tong, R. Ralston, B. Feld, 2010, Antimicrobial Agents and Chemotherapy.

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

N. Butkiewicz, F. Gheyas, X. Tong, 2006, Antimicrobial Agents and Chemotherapy.

Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.

M. Dwyer, A. Nomeir, R. Mazzola, 2016, Bioorganic & medicinal chemistry letters.

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.

X. Tong, P. Qiu, Zhuyan Guo, 2006, Biochemistry.

Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.

James I. Fells, E. Asante-Appiah, C. Coburn, 2016, Bioorganic & medicinal chemistry letters.

Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.

E. Asante-Appiah, C. Coburn, M. Dwyer, 2016, Bioorganic & medicinal chemistry letters.

Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.

E. Asante-Appiah, C. Coburn, M. Dwyer, 2016, Bioorganic & medicinal chemistry letters.

Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.

James I. Fells, E. Asante-Appiah, C. Coburn, 2016, Bioorganic & medicinal chemistry letters.

Conserved C-Terminal Threonine of Hepatitis C Virus NS3 Regulates Autoproteolysis and Prevents Product Inhibition

S. Lemon, P. Weber, B. Malcolm, 2004, Journal of Virology.

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

D. Hazuda, E. Asante-Appiah, A. Howe, 2016, Antimicrobial Agents and Chemotherapy.

Interferon in Replicon Cells Enhances the Antiviral Activity of Alpha Suppresses Polyprotein Maturation and of Hepatitis C Virus NS 3 Protease , SCH 503034 , a Mechanism-Based Inhibitor

F. Gheyas, X. Tong, C. Jiang, 2005 .

Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.

E. Asante-Appiah, C. Coburn, M. Dwyer, 2016, Bioorganic & medicinal chemistry letters.